• 1
    Covic A, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ. Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. J Nephrol 2006; 19: 78393.
  • 2
    Zoccali C. How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease? Nat Clin Pract Nephrol 2007; 4: 1789.
  • 3
    Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 107984.
  • 4
    Fagugli RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U. Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J Nephrol 2006; 19: 7783.
  • 5
    Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 416.
  • 6
    Manunta P, Iacovillo M, Forleo C et al. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertension 2005; 23: 167781.
  • 7
    Campese VM, Park J. The kidney and hypertension: over 70 years of research. J Nephrol 2006; 19: 6918.
  • 8
    Rossi GP, Manunta P, Hamlyn JM et al. Immunoreactive endogenous ouabain in primary hyperaldosteronism and essential hypertension: relationship with plasma rennin, aldosterone and blood pressure levels. J Hypertension 1995; 13: 118191.
  • 9
    Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BC, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992; 86: 4205.
  • 10
    Hamlyn JM, Hamilton BP, Manunta P. Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J Hypertension 1996; 14: 15167.
  • 11
    Tao QF, Soszynski PA, Hollenberg NK, Graves SW. Specificity of the volume-sensitive sodium pump inhibitor isolated from human peritoneal dialysate in chronic renal failure. Kidney Int 1996; 49: 4209.
  • 12
    Ritz E. Uremic cardiomyopathy – an endogenous digitalis intoxication? J Am Soc Nephrol 2006; 17: 14937.
  • 13
    Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 1998; 273: 1524956.
  • 14
    Trevisi L, Visentin B, Cusinato F, Pighin I, Luciani S. Anti-apoptotic effect of ouabain on human umbilical vein endothelial cells. BBRC 2004; 321: 71621.
  • 15
    Manunta P, Stella P, Rivera R et al. Left ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 1999; 34: 4506.
  • 16
    Pitzalis MV, Hamlyn JM, Messaggio E et al. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Failure 2006; 8: 17986.
  • 17
    Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G. Oubain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30: 88696.
  • 18
    Sahn DJ, De Maria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society if Echocardiography. Recommendations regarding quantitation on M-mode echocardiography: result of a survey of echocardiography measurements. Circulation 1978; 58: 107283.
  • 19
    Devereux RB, Alonso Dr, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necroscopy findings. Am J Cardiol 1986; 57: 4508.
  • 20
    Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 34552.
  • 21
    Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 150815.
  • 22
    Manunta P, Messaggio E, Ballabeni C et al. Salt Sensitivity Study Group of the Italian Society of Hypertension. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 2001; 38: 198203.
  • 23
    Navaneethan SD, Bonifati C, Schena FP, Strippoli GF. Evidence for optimal targets in chronic kidney disease. J Nephrol 2006; 19: 6407.
  • 24
    Bortotolotto LA, Costa-Hong V, Jorgetti V et al. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism. J Nephrol 2007; 20: 6672.
  • 25
    Hamlyn JM, Blaustein MP, Bova S et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 1991; 88: 625963.
  • 26
    Manunta P, Hamilton BP, Hamlyin JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 2006; 90: R5539.
  • 27
    Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 2004; 279: 3330614.
  • 28
    Pierdomenico SD, Bucci A, Manunta P et al. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 2001; 14: 4450.
  • 29
    Hoy W, Gibson TP, Biddle T. Digoxin removal from a patient with renal failure by hemoperfusion with Amberlite XAD-4 resin. Artif Organs 1979; 3: 1246.